Immunic, Inc. Announces Upcoming Q3 Financial Results
Immunic, Inc. (Nasdaq: IMUX), a pioneer in developing clinical therapies for chronic inflammatory and autoimmune diseases, has announced its plans to disclose financial results for the third quarter of the year, along with a comprehensive corporate update. This much-anticipated announcement is scheduled to take place prior to the opening of U.S. financial markets on a designated Thursday in early November.
Details on the Financial Results and Webcast
As part of the financial announcement, Immunic will conduct a live webcast for interested parties. The webcast, designed to provide detailed insights into the company’s financial performance and business developments, is set to begin at 8:00 am ET following the financial results announcement.
Participation in the Webcast
To join the webcast, participants are encouraged to register in advance. Registration can be completed through the dedicated section on Immunic's website. After registration, participants will receive a confirmation email containing access details, including a link for online participation and a dial-in telephone number.
Archived Webcast Replay
For those unable to attend the live session, Immunic will offer an archived replay of the webcast. It will be made available approximately one hour following the conclusion of the live event. This provides an excellent opportunity for stakeholders to catch up on the key points discussed during the presentation.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is dedicated to developing innovative therapies for chronic inflammatory and autoimmune diseases. The company’s lead candidate, vidofludimus calcium (IMU-838), is currently undergoing critical phase 2 and phase 3 clinical trials aimed at treating various forms of multiple sclerosis and ulcerative colitis. This candidate has shown promise in previous studies, positioning Immunic as a leader in these therapeutic areas.
Current Pipeline of Developments
In addition to the advancements with vidofludimus calcium, Immunic is also working on IMU-856, which is targeted at restoring intestinal barrier function—a critical component in treating diseases like celiac disease. Preparations for its phase 2 clinical trial are well underway, indicating significant progress in Immunic's research and development efforts.
Assurance of Forward-Looking Statements
The company’s communication will also contain statements regarding future strategies and the anticipated success of their development programs. These forward-looking statements will highlight the potential of Immunic's clinical pipeline while acknowledging potential risks and uncertainties inherent in the biotechnology industry.
It’s crucial for stakeholders and investors to understand that while expectations are positive, the nature of clinical trials entails many variables that could influence outcomes.
Contact Information
For more detailed inquiries or specific questions regarding the upcoming webcast, interested parties may contact the Investor Relations team at Immunic. Communications can be directed to Jessica Breu, the Vice President of Investor Relations and Communications, who is available to assist.
Frequently Asked Questions
What date will Immunic announce its Q3 financial results?
Immunic will announce its third-quarter financial results in early November, prior to the stock market opening.
How can I participate in the Immunic webcast?
Participation requires registration via Immunic's official website. After registering, you will receive access details.
What is the focus of Immunic's clinical pipeline?
Immunic's pipeline focuses primarily on therapies for chronic inflammatory and autoimmune diseases.
When will a replay of the webcast be available?
An archived replay of the live webcast will be available approximately one hour after the event concludes.
Who can I contact for more information?
For inquiries, you can reach out to Jessica Breu at Immunic, who serves as the Vice President for Investor Relations.
